Cell line · CVCL_1729
Papers62
1 to 20 of 62
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Targeting CD24 Activates Macrophages to Reduce Tumor Burden in Preclinical Models of Solid Tumors. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Beta-site Amyloid Precursor Protein Cleaving Enzyme 1 Overexpression Abrogates ST6GAL1 Mediated Rectal Cancer Chemoradiation Resistance. | Cancer Genomics Proteomics | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Tumor Invasive Border Index (TIBI) in colorectal cancer: linking infiltrative morphology to molecular insights. | J Pathol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| WEE1 kinase inhibition to overcome acquired resistance to targeted therapies in colorectal cancer. | EMBO Mol Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Constitutive EGFR Activation Induced by PTPRR Downregulation Confers Resistance to KRAS Inhibitors. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| USP10-mediated deubiquitination and activation of KRAS mutants promotes colorectal cancer via a novel USP10/KRAS positive feedback circuit. | Acta Pharm Sin B | 2026 | Its Methods give the RRID and name the line | PubMed | |
| RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer. | Nat Cell Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Class IIa HDACs forced degradation allows resensitization of oxaliplatin-resistant FBXW7-mutated colorectal cancer. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers. | Cell Rep Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRASG12C Inhibitors in Preclinical Models. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Tumor Vessel Normalization via PFKFB3 Inhibition Alleviates Hypoxia and Increases Tumor Necrosis in Rectal Cancer upon Radiotherapy. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| AMT-562, a Novel HER3-targeting Antibody-Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors. | Mol Cancer Ther | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Alternative splicing of GSDMB modulates killer lymphocyte-triggered pyroptosis. | Sci Immunol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells. | Sci Signal | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Quantitative Proteomics of the Cancer Cell Line Encyclopedia. | Cell | 2020 | Cellosaurus cites it | PubMed | |
| CoA Synthase (COASY) Mediates Radiation Resistance via PI3K Signaling in Rectal Cancer. | Cancer Res | 2020 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1729/papers